KRAS and non-small cell lung carcinoma: On May 28, 2021, the KRAS-TKI sotorasib was successfully developed and approved by the FDA for the treatment of KRAS G12C-positive NSCLC in those having received at least one previous systemic therapy, exhibiting an ORR of 36% and disease control rate (DCR) of 81% in these patients.79